Guobang Pharma (SH:605507) Xin Lang Cai Jing·2025-07-30 02:13Core Insights - Guobang Pharmaceutical (605507.SH) reported a total revenue of 3.026 billion yuan for the first half of 2025, marking an increase of 134 million yuan or 4.63% year-on-year, achieving five consecutive years of growth [1] - The net profit attributable to shareholders reached 456 million yuan, up by 50.97 million yuan or 12.60% year-on-year, indicating two consecutive years of profit growth [1] - The net cash inflow from operating activities was 103 million yuan, an increase of 353 million yuan compared to the same period last year [1] Financial Metrics - The latest debt-to-asset ratio stands at 25.41%, a decrease of 0.28 percentage points from the previous quarter [3] - The gross profit margin is reported at 26.85%, an increase of 0.42 percentage points from the previous quarter and up by 0.26 percentage points year-on-year, achieving two consecutive quarters of growth [3] - The return on equity (ROE) is 5.65%, an increase of 0.31 percentage points compared to the same period last year [3] - The diluted earnings per share (EPS) is 0.82 yuan, an increase of 0.09 yuan or 12.33% year-on-year, marking two consecutive years of growth [3] Operational Efficiency - The total asset turnover ratio is 0.28 times, while the inventory turnover ratio is 1.55 times [4] - The number of shareholders is 25,000, with the top ten shareholders holding 357 million shares, accounting for 63.85% of the total share capital [4] - The largest shareholder is Xinchang Ander Trading Co., Ltd., holding 23.08% of the shares [4]